Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2631
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcía-Gutiérrez, Valentín-
dc.contributor.authorGómez-Casares, María T-
dc.contributor.authorPuerta, José M-
dc.contributor.authorAlonso-Domínguez, Juan M-
dc.contributor.authorOsorio, Santiago-
dc.contributor.authorHernández-Boluda, Juan C-
dc.contributor.authorCollado, Rosa-
dc.contributor.authorRamírez, María J-
dc.contributor.authorIbáñez, Fátima-
dc.contributor.authorMartín, María L-
dc.contributor.authorRodríguez-Gambarte, Juan D-
dc.contributor.authorMartínez-Laperche, Carolina-
dc.contributor.authorGómez, Montse-
dc.contributor.authorFiallo, Dolly V-
dc.contributor.authorRedondo, Sara-
dc.contributor.authorRodríguez, Alicia-
dc.contributor.authorRuiz-Nuño, Concepción-
dc.contributor.authorSteegmann, Juan L-
dc.contributor.authorJiménez-Velasco, Antonio-
dc.date.accessioned2017-05-05T07:59:07Z-
dc.date.available2017-05-05T07:59:07Z-
dc.date.issued2017-03-09-
dc.identifier.citationGarcía-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. PLoS One. 2017 Mar 9;12(3):e0173532.es_ES
dc.identifier.issn1932-6203 (Online)es_ES
dc.identifier.urihttp://hdl.handle.net/10668/2631-
dc.descriptionMembers of the Spanish Group of Chronic Myeloid Leukemia (GELMC) are: Valentín García-Gutiérrez (Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain). María T. Gómez-Casares (Hematology Department, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain). José M. Puerta (Unidad de Gestión Clínica Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain). Juan M. Alonso-Domínguez (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain). Santiago Osorio (Hematology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain). Juan C. Hernández-Boluda (Hematology Department, Hospital Clínico, Valencia, Spain). Rosa Collado (Genetic Laboratory, Hematology Department, Consorcio Hospital General Universitario, Valencia, Spain). María J. Ramírez (Hematology Department, Hospital de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain). Fátima Ibáñez (Hematology Department, Hospital San Pedro de Alcántara, Cáceres, Spain). Alicia Rodríguez (Hematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain). Concepción Ruiz-Nuño and Antonio Jiménez-Velasco (Hematology Department, Hospital Regional Universitario de Málaga, IBIMA, Spain). Juan L. Steegmann (Hematology Department & IIS-IP. Hospital Universitario de la Princesa, Madrid, Spain.es_ES
dc.description.abstractIn chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlated with further outcomes. Monitoring molecular responses in CML using the GeneXpert (Cepheid) platform has shown an optimal correlation with standardized RQ-PCR (IS) when measuring BCR-ABL1 levels lower than 10%, as it is not accurate for values over 10%. The aim of the present study was to determine the predictive molecular value at three months on different outcome variables using the Xpert BCR-ABL1 MonitorTM assay (Xpert BCR-ABL1). We monitored 125 newly diagnosed consecutive CML patients in the chronic phase (CML-CP) using an automated method: Xpert BCR-ABL1. Only 5% of patients did not achieve an optimal response at 3 months, and the 10% BCR-ABL1 cutoff defined by RQ-PCR (IS) methods was unable to identify significant differences in the probabilities of achieving a complete cytogenetic response (CCyR) (50% vs. 87%, p = 0.1) or a major molecular response (MMR) (60% vs. 80%, p = 0.29) by 12 months. In contrast, a cutoff of 1.5% more accurately identified differences in the probabilities of achieving CCyR (98% vs. 54%, p<0.001) and MMR (88% vs. 56%, p<0.001) by 12 months, as well as probabilities of treatment changes (p = 0.005). Therefore, when using the Xpert BCR-ABL1 assay, a cutoff of 1.5% at 3 months could with high probability identify patients able to achieve an optimal response at 12 months.es_ES
dc.description.sponsorshipThis work was partially supported by grants from the Asociación Malagueña para la Investigación en Leucemia (AMPILE). Dr. García-Gutierrez has received a consultancy fee and research funding and has served as a member on the board of directors or advisory committees for Novartis, Bristol-Myers Squibb, Pfizer and Ariad. Dr. Steegmann has received a consultancy fee and honoraria and has received research funding and participated on the Speaker’s bureau for Novartis, Bristol-Myers Squibb, Pfizer and Ariad.es_ES
dc.language.isoenes_ES
dc.publisherPublic Library of Sciencees_ES
dc.relation.ispartofPloS Onees_ES
dc.subjectHumanoses_ES
dc.subjectLeucemia mielógena crónica BCR-ABL positivaes_ES
dc.subjectLeucemia mieloide de fase crónicaes_ES
dc.subjectReacción en cadena de la polimerasaes_ES
dc.subjectProbabilidades_ES
dc.subjectEstándares de referenciaes_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positivees_ES
dc.subject.meshMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive::Leukemia, Myeloid, Chronic-Phasees_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Nucleic Acid Amplification Techniques::Polymerase Chain Reactiones_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probabilityes_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Weights and Measures::Reference Standardses_ES
dc.titleA BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemiaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.versionYeses_ES
dc.contributor.groupSpanish Group of Chronic Myeloid Leukemia (GELMC)es_ES
dc.identifier.pmid28278193es_ES
dc.rights.accessRightsAcceso abiertoes_ES
dc.identifier.doi10.1371/journal.pone.0173532es_ES
dc.type.versioninfo:eu-repo/semantics/publishedes_ES
dc.relation.publisherversionhttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173532#abstract0es_ES
dc.contributor.authoraffiliation[García-Gutiérrez,V; Rodríguez-Gambarte,JD] Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Gómez-Casares,MT; Fiallo,DV] Hematology Department, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain. [Puerta,JM] Unidad de Gestión Clínica Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Alonso-Domínguez,JM] Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. [Osorio,S; Martínez-Laperche,C; Redondo,S] Hematology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain. [Hernández-Boluda,JC; Gómez,M] Hematology Department, Hospital Clínico, Valencia, Spain. [Collado,R] Genetic Laboratory, Hematology Department, Consorcio Hospital General Universitario, Valencia, Spain. [Ramírez,MJ] Hematology Department, Hospital de Jerez de la Frontera, Cádiz, Spain. [Ibáñez,F] Hematology Department, Hospital San Pedro de Alcántara, Cáceres, Spain. [Martín,ML; Rodríguez,A] Hematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Ruiz-Nuño,C; Jiménez-Velasco,A] Hematology Department, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain. [Steegmann,JL] Hematology Department & IIS-IP, Hospital Universitario de la Princesa, Madrid, Spain.es_ES
Appears in Collections:01- Artículos - Complejo Hospitalario Universitario de Granada
01- Artículos - Hospital de Jerez
01- Artículos - Hospital Regional de Málaga
01- Artículos - Hospital Virgen Macarena
01- Artículos - IBIMA. Instituto de Investigación Biomédica de Málaga

Files in This Item:
File Description SizeFormat 
GarciaGutierrez_ABCR-ABL1.pdfArtículo publicado767,75 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons